- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03938363
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia (GAIT-TOX)
Analyse de la Marche de Patients Atteints de Dystonie Focale Avant et après Traitement Par Toxine Botulique
Efficient gait requires effective postural control, both static and dynamic. Hence, postural disorders may affect gait. Yet, very little is known about the specific effects of focal postural disorders such as cervical dystonia (CD) and blepharospasm (BS) on patients' mobility.
The present research therefore aims at analyzing gait characteristics in patients presenting with these conditions in order to document possible gait alterations.
In addition, the investigators will explore the effect of botulinum toxin treatment, which the most frequently used therapeutic option, on the patients' gait characteristics. Indeed, while the treatment improves both dystonia and pain, and therefore quality of life, its influence on gait is presently unknown. the investigators aim at filling this knowledge gap
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot monocentric, non-randomized, controlled study. The total duration of the project is 24 months. For each patient, the total duration of the study will be one month.
The primary goal is to study gait parameters in patients with focal dystonia (CD and BS) before and after botulinum toxin treatment.
The secondary goal is to study interactions between dystonia severity and gait disorders, if gait disorders are objectified. The investigators will also examine whether botulinum toxin treatment affects gait parameters.
The main dependent variable regarding gait analysis will be gait velocity, as it is the most relevant functional variable for the patients. Gait velocity will be measured on the ground using the 10 Meter Walk Test (10MWT). Gait velocity will thereafter be adjusted to the treadmill to be the most comfortable. Spatial and temporal gait parameters will also be analyzed, namely: step frequency, step length, step length variability, gait asymmetry, and side with the shortest step length.
To examine the influence of dystonia severity on gait parameters, the investigators will examine possible links between the gait parameters and dystonia severity as reflected by the global scores of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for cervical dystonia and the Jankovic Rating Scale (JRS) for blepharospasm.
In order to evaluate the effects of the botulinum toxin on gait parameters, the investigators will compare gait variables before and after toxin treatment in the patient groups. If gait parameters are influenced by the treatment, the investigators will compare the post treatment data with the data of the healthy control group. In addition, the investigators will perform a patient satisfaction scale (Patient Global Impression of Change) on the change of walking parameters.
For this pilot, longitudinal, prospective, controlled study, the investigators will include two groups of 10 patients (patients with DC, patients with BS, naive or not about botulinum toxin treatment) and two groups of 10 age- and sex-matched healthy control subjects.
After collecting demographical information, severity of dystonia will be assessed using the relevant Dystonia scale (for the patients' groups).
Participants will then be shortly trained walking on a treadmill. Thereafter, they will be required to walk on a BIODEX treadmill enabling recording of all targeted gait parameters. For the patients' groups, gait parameters will be recorded both before and 4-5 weeks after the injection.
At the firth visit, the duration of assessments and treatment for the patients will be about 1.5 hour. At the second visit, assessment will last about 30 minutes.
To examine the influence of dystonia (CD, BS) on gait velocity and parameters, patients and matched healthy control data will be compared using the Mann-Whitney non parametric test. To examine the influence of botulinum toxin injection in each group of patients, data will be compared using the Wilcoxon test. Pearson correlation will be used to examine possible links between dystonia severity and gait parameters alterations.
This study will contribute to improving our knowledge on the effects of focal dystonia on gait, thus enabling an improvement in the design of rehabilitation programs. It will also document the effect of botulinum toxin on gait, thus contributing to a better guidance of this treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Isere
-
La Tronche, Isere, France, 38700
- Chu Grenoble Alpes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- speaking French, in the ability to understand clinical tests and explorations,
- in ability to move to the CHU Grenoble Alpes
- Diagnosis of cervical dystonia or isolated Blepharospasm,
- Absence of neurological or psychiatric disorders,
- Affiliation to a health insurance,
- Signed consent fo the subject.
Exclusion Criteria:
- Pregnant women (positive pregnancy test), parturient or breastfeeding
- Cervical dystonia or Blepharospasm of secondary origin
- subjects having benefited from deep brain stimulation,
- History of other pathologies that may lead to walking disorders, inability to walk without technical assistance, inability to walk for more than 10 minutes,
- Subjects receiving botulinum toxin treatment for another cause.
Prohibited treatments and procedures:
- Antecedent of pathologies that may cause walking disorders
- Simultaneous participation in another Interventional study
- Subject in time of exclusion from another study
- Subject under guardianship or having curators (major protected)
- Subject under administrative or judicial supervision
- Subject not able to be contacted in case of emergency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cervical Dystonia (CD)
Patients with cervical dystonia
|
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
injection of Botulinum Toxin in the two groups of CD and BS
Other Names:
JRS for BS TWSTRS for CD
Other Names:
|
Placebo Comparator: Healthy Control CD
CD age- and sex-matched healthy control subjects
|
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
|
Experimental: Blepharospasm (BS)
Patients with blepharospasm
|
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
injection of Botulinum Toxin in the two groups of CD and BS
Other Names:
JRS for BS TWSTRS for CD
Other Names:
|
Placebo Comparator: Healthy Control BS
BS age- and sex-matched healthy control subjects
|
Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
gait velocity
Time Frame: 5 minutes
|
comfortable gait velocity on the treadmill
|
5 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
step frequency
Time Frame: 5 minutes
|
registration on the treadmill
|
5 minutes
|
step length
Time Frame: 5 minutes
|
registration on the treadmill
|
5 minutes
|
step length asymmetry
Time Frame: 5 minutes
|
registration on the treadmill
|
5 minutes
|
shortest step side
Time Frame: 5 minutes
|
registration on the treadmill
|
5 minutes
|
step length variability
Time Frame: 5 minutes
|
registration on the treadmill
|
5 minutes
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tarsy D, Simon DK. Dystonia. N Engl J Med. 2006 Aug 24;355(8):818-29. doi: 10.1056/NEJMra055549. No abstract available.
- Barr C, Barnard R, Edwards L, Lennon S, Bradnam L. Impairments of balance, stepping reactions and gait in people with cervical dystonia. Gait Posture. 2017 Jun;55:55-61. doi: 10.1016/j.gaitpost.2017.04.004. Epub 2017 Apr 4.
- Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73. doi: 10.1002/mds.25475. Epub 2013 May 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Eyelid Diseases
- Dystonia
- Dystonic Disorders
- Torticollis
- Blepharospasm
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
- 38RC18.107
- 2019-A00502-55 (Other Identifier: ID RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blepharospasm
-
HugelCompletedEssential BlepharospasmKorea, Republic of
-
Medy-ToxCompletedEssential BlepharospasmKorea, Republic of
-
HugelCompletedEssential BlepharospasmKorea, Republic of
-
Medy-ToxCompleted
-
University of FloridaCompletedBenign Essential BlepharospasmUnited States
-
University Hospital, GrenobleCompletedBlepharospasm, Benign EssentialFrance
-
Merz Pharmaceuticals GmbHCompletedBilateral Blepharospasm (BEB)Greece, Malaysia, Sri Lanka
-
Silkiss Eye SurgeryJazz Pharmaceuticals; Smith-Kettlewell Eye Research Institute; Benign Essential...CompletedCBD | Blepharospasm | Blepharospasm, Benign EssentialUnited States
-
Oxford University Hospitals NHS TrustThe Dystonia Society of the United Kingdom; Globsource UK; Statsconsultancy Ltd...CompletedBlepharospasm
-
National Institute of Neurological Disorders and...Completed
Clinical Trials on Treadmill
-
California State University, SacramentoSeattle Children's Hospital; Thrasher Research Fund; University of Puget SoundCompletedIntensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral PalsyCerebral PalsyUnited States
-
University of MinnesotaCompletedSedentary Lifestyle | Risk Factor, CardiovascularUnited States
-
Marquette UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingMultiple SclerosisUnited States
-
Imam Abdulrahman Bin Faisal UniversityNot yet recruitingCerebral PalsySaudi Arabia
-
Cliniques universitaires Saint-Luc- Université...UnknownParkinson Disease | Gait Disorders, NeurologicBelgium
-
University of Erlangen-NürnbergGerman Foundation for Neurology; Department of Molecular Neurology, Faculty...Completed
-
Ospedale Generale Di Zona Moriggia-PelasciniUnknownParkinson Disease | Gait Disorders, Neurologic | TreadmillItaly
-
Fondazione Don Carlo Gnocchi OnlusUnknownStroke | Multiple Sclerosis | Parkinson DiseaseItaly
-
Riphah International UniversityCompleted
-
Becerra, PabloTerminatedRehabilitation | Ankle Fractures | Trigger Point Pain, Myofascial | Pain Measurement | Physical Therapy Modalities | NeedlesChile